UB Paderborn / Katalog / Suche / in CDI

Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency

Journal of allergy and clinical immunology, 2012-10, Vol.130 (4), p.951-957.e11

2012

Link zum Volltext

Verfügbarkeit prüfen

Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials

BMC immunology, 2020-05, Vol.21 (1), p.24-24, Article 24

2020

Link zum Volltext

Verfügbarkeit prüfen

Analysis of Safety and Tolerability Data in Pediatric Patients with Primary Immunodeficiency Diseases from Two Phase 2/3 Studies of Human Immune Globulin Subcutaneous, 20

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB217-AB217

2017

Link zum Volltext

Verfügbarkeit prüfen

Partial Impairment of Cytokine Responses in Tyk2-Deficient Mice

Immunity (Cambridge, Mass.), 2000-10, Vol.13 (4), p.549-560

2000

Link zum Volltext

Verfügbarkeit prüfen

Review of the Onboarding Experience of a New 20% Human Immune Globulin for Subcutaneous Administration (SCIG 20%): Correlation of Infusion Parameters and Adverse Events (AEs)

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB216-AB216

2017

Link zum Volltext

Verfügbarkeit prüfen

A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB216-AB216

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North America

Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.AB221-AB221

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (IGHy) in Patients with Primary Immunodeficiency Disease (PIDD): Infections over Time

Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.AB219-AB219

2016

Link zum Volltext

Verfügbarkeit prüfen

Local Adverse Reaction Rates Decreased over Time during Treatment with Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IGHy) in Patients with Primary Immunodeficiency Disorders in the IGHy Phase 3 Studies

Journal of allergy and clinical immunology, 2016-02, Vol.137 (2), p.AB220-AB220

2016

Link zum Volltext

Verfügbarkeit prüfen

Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients With Immunodeficiencies Receiving Weekly Immune Globulin Subcutaneous [Human] 20% Solution (Ig20Gly)

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB216

2020

Link zum Volltext

Verfügbarkeit prüfen

Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin

Journal of clinical immunology, 2021-08, Vol.41 (6), p.1331-1338

2021

Link zum Volltext

Verfügbarkeit prüfen

60 Assessing hyaluronidase-facilitated subcutaneous immunoglobulin 20% (fSCIG 20%) pharmacokinetics, safety and tolerability in primary immunodeficiency diseases: phase 2/3 study design

Clinical immunology (Orlando, Fla.), 2024-05, Vol.262, p.110002, Article 110002

2024

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases

International immunopharmacology, 2021-11, Vol.100, p.108044, Article 108044

2021

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases

International immunopharmacology, 2019-06, Vol.71, p.404-410

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America

Journal of clinical immunology, 2016-10, Vol.36 (7), p.700-712

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in US pediatric patients with primary immunodeficiency disease

Clinical immunology (Orlando, Fla.), 2023-05, Vol.250, p.109598, Article 109598

2023

Link zum Volltext

Verfügbarkeit prüfen

Ig20Gly Tolerability and Infusion Characteristics in Pediatric and Advanced Age Patients With Primary Immunodeficiency Diseases

Journal of allergy and clinical immunology, 2019-02, Vol.143 (2), p.AB116-AB116

2019

Link zum Volltext

Verfügbarkeit prüfen

Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases

Annals of allergy, asthma, & immunology, 2019-09, Vol.123 (3), p.271-279.e1

2019

Link zum Volltext

Verfügbarkeit prüfen

Onboarding Experience of Pediatric Patients With Primary Immunodeficiency Diseases With Subcutaneous Human Immune Globulin 20% (Ig20Gly)

Journal of allergy and clinical immunology, 2018-02, Vol.141 (2), p.AB268-AB268

2018

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study

Immunotherapy, 2024-06, p.1-13

2024

Link zum Volltext

Verfügbarkeit prüfen

Long-term safety of facilitated subcutaneous immunoglobulin treatment in pregnant women with primary immunodeficiency diseases: results from a registry study

Immunotherapy, 2022-06, Vol.14 (8), p.609-616

2022

Link zum Volltext

Verfügbarkeit prüfen

Onboarding Experience of Patients With Primary Immunodeficiency Diseases Who Switched to Subcutaneous Human Immune Globulin 20% (Ig20Gly) From Intravenous or Subcutaneous Immune Globulin 10

Journal of allergy and clinical immunology, 2018-02, Vol.141 (2), p.AB26-AB26

2018

Link zum Volltext

Verfügbarkeit prüfen

Infusion Parameters and Adverse Events in Patients With Primary Immunodeficiency Diseases Who Switched to Subcutaneous Human Immune Globulin 20% (Ig20Gly) From Intravenous or Subcutaneous Immune Globulin

Journal of allergy and clinical immunology, 2018-02, Vol.141 (2), p.AB267-AB267

2018

Link zum Volltext

Verfügbarkeit prüfen

Severe bilateral corneal injury attributed to a preservative-containing eye lubricant

Anesthesiology (Philadelphia), 2000-12, Vol.93 (6), p.1545-1546

2000

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study

Immunotherapy advances, 2024-01, Vol.4 (1), p.ltae001-ltae001

2024

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency

Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials

Analysis of Safety and Tolerability Data in Pediatric Patients with Primary Immunodeficiency Diseases from Two Phase 2/3 Studies of Human Immune Globulin Subcutaneous, 20

Partial Impairment of Cytokine Responses in Tyk2-Deficient Mice

Review of the Onboarding Experience of a New 20% Human Immune Globulin for Subcutaneous Administration (SCIG 20%): Correlation of Infusion Parameters and Adverse Events (AEs)

A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America

Efficacy, Safety, Tolerability, and Pharmacokinetics of Human Immune Globulin Subcutaneous, 20% (IGSC 20%): Final Analysis of a Phase 2/3 Study in Patients with Primary Immunodeficiency Disease (PIDD) in North America

Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (IGHy) in Patients with Primary Immunodeficiency Disease (PIDD): Infections over Time

Local Adverse Reaction Rates Decreased over Time during Treatment with Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IGHy) in Patients with Primary Immunodeficiency Disorders in the IGHy Phase 3 Studies

Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients With Immunodeficiencies Receiving Weekly Immune Globulin Subcutaneous [Human] 20% Solution (Ig20Gly)

Steady-State Serum IgG Trough Levels Are Adequate for Pharmacokinetic Assessment in Patients with Immunodeficiencies Receiving Subcutaneous Immune Globulin

60 Assessing hyaluronidase-facilitated subcutaneous immunoglobulin 20% (fSCIG 20%) pharmacokinetics, safety and tolerability in primary immunodeficiency diseases: phase 2/3 study design

Population pharmacokinetic simulation of varied Immune Globulin Subcutaneous (Human), 20% solution (Ig20Gly) loading and maintenance dosing regimens in immunoglobulin-naïve patients with primary immunodeficiency diseases

Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases

Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America

Efficacy and safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in US pediatric patients with primary immunodeficiency disease

Ig20Gly Tolerability and Infusion Characteristics in Pediatric and Advanced Age Patients With Primary Immunodeficiency Diseases

Tolerability of Ig20Gly during onboarding in patients with primary immunodeficiency diseases

Onboarding Experience of Pediatric Patients With Primary Immunodeficiency Diseases With Subcutaneous Human Immune Globulin 20% (Ig20Gly)

Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study

Long-term safety of facilitated subcutaneous immunoglobulin treatment in pregnant women with primary immunodeficiency diseases: results from a registry study

Onboarding Experience of Patients With Primary Immunodeficiency Diseases Who Switched to Subcutaneous Human Immune Globulin 20% (Ig20Gly) From Intravenous or Subcutaneous Immune Globulin 10

Infusion Parameters and Adverse Events in Patients With Primary Immunodeficiency Diseases Who Switched to Subcutaneous Human Immune Globulin 20% (Ig20Gly) From Intravenous or Subcutaneous Immune Globulin

Severe bilateral corneal injury attributed to a preservative-containing eye lubricant

Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study

Suchergebnisse filtern